Use of preferentially replicating bacteria for the treatment of cancer

Journal of Clinical Investigation

Volumn 105, Issue 8, 2000, Pages 1027-1030

  Sznol, Mario ^a   Lin, Stanley L ^a   Bermudes, David ^a   Zheng, Li Mou ^a   King, Ivan ^a  

^a Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL COLONIZATION; BIOTECHNOLOGY; CANCER INHIBITION; CANCER THERAPY; GENE TRANSFER; GENETIC MANIPULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHIMURIUM;

EID: 0034102281     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9818     Document Type: Review

References (18)

1. Pawelek, J.M., Low, K.B., and Bermudes, D. 1997. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537-4544.
2. Mose, J.R., and Mose, G. 1964. Oncolysis by Clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic Clostridia against the Ehrlich carcinoma. Cancer Res. 24:212-216.
3. Kops, S.K., et al. 1997. Salmonella typhimurium as an anti-cancer vector: localization within solid tumors. Proc. Am. Assoc. Cancer Res. 38:7. (Abstr.)
4. Thiele, E.H., Arison, R.N., and Boxer, G.E. 1964. Oncolysis by Clostridia. III. Effects of Clostridia and chemothorapeutic agents on rodent tumors. Cancer Res. 24:222-231.
5. Engelbart, K., and Gericke, D. 1964. Oncolysis by Clostridia. V. Transplanted tumors of the hamster. Cancer Res. 24:239-243.
6. Carey, R.W., Holland, J.F., Whang, H.Y., Netter, E., and Bryant, B. 1967. Clostridial oncolysis in man. Eur. J. Cancer. 3:37-46.
7. Lemmon, M.J., et al. 1997. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4:791-796.
8. Fox, M.E., et al. 1996. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia [erratum 1996, 3:741]. Gene Ther. 3:173-178.
9. Low, K.B., et al. 1999. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo [see comments]. Nat. Biotechnol. 17:37-41.
10. Clairmont, C., et al. 1999. VNP20009, a genetically modified Salmonella typhimurium: anti-tumor efficacy, toxicology, and biodistribution in pre-clinical models. Clin. Cancer Res. 5(Suppl.):102. (Abstr.)
11. Zheng, L.M., et al. 1997. Attenuated Salmonella typhimurium inhibited tumor metastasis in vivo. Proc. Am. Assoc. Cancer Res. 38:9. (Abstr.)
12. Somerville, J.E., Jr., Cassiano, L.,and Darveau, R.P 1999. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. 67:6583-6590.
13. Guilloteau, L.A., Lax, A.J., MacIntyre, S., and Wallis, T.S. 1996. The Salmonella dublin virulence plasmid does not modulate early T-cell responses in mice. Infect. Immun. 64:222-229.
14. Chen, J.J., Sun, Y., and Nabel, G.J. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282:1714-1717.
15. Schmitt, C.A., Schwaeble, W., Wittig, B.M., Meyer zum Buschenfelde, K.H., and Dippold, W.G. 1999. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP). CD55 (DAF) and CD59 in gastrointestinal tumours. Eur. J. Cancer. 35:117-124.
16. Thorsteinsson, L., O'Dowd, G.M., Harrington, P.M., and Johnson, P.M. 1998. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS, 106:869-878.
17. Jain, R.K. 1991. Haemodynamic and transport barriers to the treatment of solid tumours. Int. J. Radiat. Biol. 60:85-100.
18. Galan, J.E., and Collmer, A. 1999. Type III secretion machines: bacterial devices for protein delivery into host cells. Science: 284:132-138.